Data is a real-time snapshot *Data is delayed at least 15 minutes. Personalize which data points you want to see and create visualizations instantly. In 2017, it moved into oncology and infectious disease with a digital cancer chemotherapy pill. The news comes months after reports that the company had furloughed staff and couldn't secure additional funding for its ingestible-sensor business.
These would likely play a role when courting new investors – or in convincing prior backers to keep ponying up, and that their millions weren't misspent.
But with roughly 300 people on staff, according to LinkedIn, that money may not last long. http://www.rwjf.org/content/dam/farm/reports/reports/2010/rwjf54583, https://journals.sagepub.com/doi/10.1177/1060028018765159, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711878/, https://www.cdc.gov/bloodpressure/facts.htm, https://professional.diabetes.org/sites/professional.diabetes.org/files/media/fast_facts_8-2017_pro_3.pdf, About 1 in 4 people suffer from two or more chronic conditions such as hypertension or type-2 diabetes, 84% of U.S. healthcare spending is on patients with chronic conditions, More than 50% of prescribed medications are not taken as directed, Quickly decode patterns around medication adherence and patient behaviors, Make objective decisions about when to initiate, titrate, and eliminate medicine, Optimize treatment therapies and get patients to goal faster, Engage in richer, more meaningful conversations with patients based on clear, objective data, Provides visibility into medication-taking patterns, Increases connectivity to the patient’s care team, Allows for more relevant conversations with healthcare providers, 144 patients with uncontrolled hypertension used Proteus for two weeks, Identified root cause of uncontrolled hypertension in all patients Mean systolic BP decreased by 10 mm Hg and diastolic BP decreased by 5 mm Hg, 39 patients at 15 community pharmacies used Proteus for two weeks, 91% of pharmacists noted Proteus enabled them to provide data- based counseling and recommendations, 109 subjects with uncontrolled type 2 diabetes (A1C > 7%) and hypertension (systolic BP ≥ 140 mm Hg) across 13 sites used Proteus Discover with Digital Medicines or received usual care. Proteus Digital Health, maker of an ingestible sensor for tracking medication adherence, filed for Chapter 11 bankruptcy protection yesterday. Developer of digital medicine technology intended to service the needs of doctors and health systems. The board of directors appointed Lawrence Perkins as its interim chief executive officer after a stint as a chief restructuring officer.
After-hours answering services available to report issues and schedule a call-back. A digital sensor the size of a grain of sand is housed in a pill.
Proteus acknowledged to CNBC that it's undergoing a "restructuring. 3Sabaté E. Adherence to long-term therapies: evidence for action. Once the ingestible sensor reaches the stomach, it transmits a signal to the patch worn on the torso. Regarding its plans to close the Hayward sites at 3956 Point Eden Way and 3911 Trust Way and cut 90 jobs, Proteus said, “The entire facility, consisting of two buildings will be closed and all operations will cease.
Proteus Digital Health has spent two decades trying to develop "smart pills"that can be used to tell a smartphone app whether patients have taken …